Abvance Therapeutics

Abvance Therapeutics is a private, pre-clinical-stage biotech focused on revolutionizing diabetes management. Its core innovation is a combination therapy (ABV101) that pairs insulin with glucagon to proactively prevent hypoglycemia, aiming to free patients from the constant fear of low blood sugar crashes and enable better glycemic control. The company, founded in 2020, is built on a deeply personal mission and scientific foundations from Vanderbilt University, and is currently advancing its lead candidate toward clinical development while seeking strategic partnerships.

Platform focused on combining insulin with glucagon to create a built-in safety net against hypoglycemia, enabling more confident dosing and better glycemic control.

Abvance competes in the crowded diabetes space dominated by giants like Novo Nordisk, Eli Lilly, and Sanofi. It differentiates by directly targeting hypoglycemia fear with a combination approach, competing against next-gen 'smart' insulins and adjunctive therapies from other biotechs.